Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Clinical trial NCT06617429 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06617429
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-03
- Primary completion
- 2026-07-10
- Enrollment
- 129
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.